We are live on
!
Find out more
Iovance Biotherapeutics
IOVA
IOVA
122 hedge funds and large institutions have $1.31B invested in Iovance Biotherapeutics in 2018 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 52 increasing their positions, 18 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
514% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 7
391% more call options, than puts
Call options by funds: $7.71M | Put options by funds: $1.57M
350% more funds holding in top 10
Funds holding in top 10: 2 → 9 (+7)
189% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 18
185% more capital invested
Capital invested by funds: $461M → $1.31B (+$852M)
40% more funds holding
Funds holding: 87 → 122 (+35)
7.58% more ownership
Funds ownership: 79.36% → 86.94% (+7.6%)
Holders
122
Holders Change
+35
Holders Change %
+40.23%
% of All Funds
2.8%
Holding in Top 10
9
Holding in Top 10 Change
+7
Holding in Top 10 Change %
+350%
% of All Funds
0.21%
New
43
Increased
52
Reduced
18
Closed
7
Calls
$7.71M
Puts
$1.57M
Net Calls
+$6.14M
Net Calls Change
+$5.54M
Top Buyers
Top Sellers
| 1 |
BC
Broadfin Capital
New York
|
-$21.6M |
| 2 |
JP Morgan Chase
New York
|
-$11.4M |
| 3 |
Axa
Paris,
France
|
-$8.85M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
-$4.5M |
| 5 |
Millennium Management
New York
|
-$2.11M |
